ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >GPCR & G Protein >S1P Receptor modulators >BAF-312(SiponiMod)

BAF-312(SiponiMod)

BAF-312(SiponiMod) Structure
CAS No.
1230487-00-9
Chemical Name:
BAF-312(SiponiMod)
Synonyms
SiponiMod;Siponimod (BAF-312);SIPONIMOD; SIPONIMOD [INN]; BAF-312; BAF 312;(E)-1-(4-(1-(4-cyclohexyl-3-(trifluoromethyl)benzyloxyimino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid;CS-1753;Sinimod;Siponimod D11;Siponimod [INN];BAF-312(SiponiMod);Formyl sitagliptin d4
CBNumber:
CB62725945
Molecular Formula:
C29H35F3N2O3
Molecular Weight:
516.59
MOL File:
1230487-00-9.mol
MSDS File:
SDS
Modify Date:
2025/4/17 18:22:24

BAF-312(SiponiMod) Properties

Melting point 154 - 157°C
Boiling point 602.0±65.0 °C(Predicted)
Density 1.24±0.1 g/cm3(Predicted)
storage temp. Hygroscopic, Refrigerator, under inert atmosphere
solubility DMSO (Slightly), Methanol (Slightly)
pka 2.69±0.20(Predicted)
form Solid
color White to Off-White
InChIKey KIHYPELVXPAIDH-HNSNBQBZSA-N
SMILES N1(CC2=CC=C(/C(=N/OCC3=CC=C(C4CCCCC4)C(C(F)(F)F)=C3)/C)C=C2CC)CC(C(O)=O)C1

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P280-P301+P312-P302+P352-P305+P351+P338
NFPA 704
0
2 0

BAF-312(SiponiMod) Chemical Properties,Uses,Production

Description

S1p signaling is important for immune, cardiovascular, and CNS function.Like its FDA approved predecessor fingolimod, siponimod is an oral S1p signaling modulator.While fin- golimod binds four out of five known S1p receptors, siponimod is selective for receptor sub- types 1 and 5. This selectivity may allow for an improved adverse event profile.

Uses

Siponimod is a functional sphingosine -1 phosphate (SIP) antagonist used in the treatment of multiple sclerosis and other central nervous system-related diseases in human subjects. .

Side effects

Siponimod,2 mg/day, was studied in a Phase I placebo-controlled trial in patients with secondary progressive Ms.206The primary endpoint was time to 3 months confirmed dis- ability progression. There were substantive side effects from the drug,mainly increased liver transaminase concentrations,bradycardia, and bradyarrhythmia at treatment initiation.With subsequent siponimod administration,there was an increased incidence of macular edema, hypertension,varicella zoster reactivation, and convulsions compared to placebo. By grad- ually escalating the initial dose of siponimod, cardiac first-dose effects were reduced.While the results of this trial are encouraging,long- term safety issues may be a greater concern5or since persons with secondary progressive MS as a group are older,with a higher incidence of comorbidities that could preclude use of siponimod.

BAF-312(SiponiMod) Preparation Products And Raw materials

Global( 187)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
SIMSON PHARMA LIMITED +91-8291074273 Shanghai, India 228 58 Inquiry
Dr. Reddy's Laboratories Ltd +91-4049002900 +91-4049002900 Hyderabad, India 165 58 Inquiry
Venkatasai Life Sciences +91-9908134868 +91-8008303069 Hyderabad, India 186 58 Inquiry
Maithri Drugs Pvt Ltd +91-9059204566 +91-9848881740 Telangana, India 64 58 Inquiry
SynZeal Research Pvt Ltd +1 226-802-2078 Gujarat, India 6514 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6257 58 Inquiry
Hangzhou MolCore BioPharmatech Co.,Ltd. +86-057181025280; +8617767106207 China 49734 58 Inquiry
Shijiazhuang Dingmin Pharmaceutical Sciences Co., Ltd. +86-0311-67591193 +8613931880626 China 256 58 Inquiry
Hebei Mujin Biotechnology Co.,Ltd +86 13288715578 +8613288715578 China 12809 58 Inquiry
Wuhan Haorong Biotechnology Co.,ltd +86-18565342920; +8618565342920 China 305 58 Inquiry

Related articles

  • The introduction of Siponimod
  • Siponimod is an oral selective sphingosine 1-phosphate receptor subtypes 1 and 5 (S1PR1,5) modulator being developed by Novart....
  • Jan 16,2024

BAF-312(SiponiMod) Spectrum

BAF-312(SiponiMod) 3-Azetidinecarboxylic acid, 1-[[4-[(1E)-1-[[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]- 1-(4-[1-[(E)-4-Cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl-benzyl)-azetidine-3-carboxylic acid BAF312 (Siponimod) 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Siponimod [INN] CS-1753 BAF-312(SiponiMod) USP/EP/BP Siponimod D11 SiponiMod (E)-1-(4-(1-(4-cyclohexyl-3-(trifluoromethyl)benzyloxyimino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid Siponimod (BAF-312) SIPONIMOD; SIPONIMOD [INN]; BAF-312; BAF 312 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Formyl sitagliptin d4 Sinimod Siponimod, 10 mM in DMSO 1230487-00-9 C29H35F3N2O3 API Inhibitors